Other names on the Nifty Pharma index that has a significant upside potential include Aurobindo Pharma and Ajanta Pharma, both of which have an upside potential of 23%.

Indian pharma stocks fell for the third consecutive session amid concerns of potential US tariffs on pharmaceutical imports.

India pharmaceutical stocks soared today after US President Donald Trump imposed a 26% reciprocal tariff on India but excluded the pharma sector from the levies.

Granules India's plan is expected to reduce the number of legal entities, simplify the legal, tax, and operational structures, create a unified holding structure, and improve the market focus.

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

In the vast realm of traditional Chinese medicine (TCM), there are countless formulations that have stood the test of time, ...

Telangana: Granules India has announced the appointment of Dr P.N. Baskaran as President - Head API Manufacturing & ...

Granules Europe Limited, a wholly owned foreign subsidiary of Granules India situated at Bath, United Kingdom has been ...

The NSE Nifty 50 on Tuesday rose 0.04% to 23,668.65 after crossing 23,800 intraday, while the BSE Sensex ended 0.04% higher.